Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: SENSORION

Market Cap 126M 146M 116M 109M 205M 13.8B 207M 1.37B 535M 6.77B 549M 537M 23.42B P/E 2026 *
-16.3x
P/E 2027 * -3.77x
Enterprise Value -5.89M -6.83M -5.42M -5.1M -9.58M -645M -9.66M -64.21M -25M -316M -25.64M -25.09M -1.09B EV / Sales 2026 *
-0.27x
EV / Sales 2027 * 19.7x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-0.51%-12.53%-10.84% 43.44B
+1.30%+7.24%+300.79%+523.19% 33.54B
-3.08%-8.34%+7.34%-22.78% 28.48B
+2.33%+3.91%+6.99%+41.17% 29.2B
+0.06%+4.36%+13.31%+21.11% 25.34B
+1.33%+8.82% - - 14.36B
-0.06%-3.93%+50.79%+102.59% 13.05B
+0.10%-2.70%+3.47%+4.33% 12.67B
-1.10%+0.16%+99.78%+80.03% 12.28B
Average +0.07%+1.33%+58.74%+92.35% 23.6B
Weighted average by Cap. +0.07%+1.35%+61.75%+103.75%

Financials

2026 *2027 *
Net sales 21.86M 25.34M 20.1M 18.91M 35.54M 2.39B 35.84M 238M 92.72M 1.17B 95.09M 93.06M 4.06B 6.4M 7.41M 5.88M 5.53M 10.4M 700M 10.49M 69.68M 27.13M 343M 27.82M 27.23M 1.19B
Net income -4.34M -5.03M -3.99M -3.76M -7.06M -475M -7.12M -47.29M -18.41M -233M -18.88M -18.48M -806M -50.64M -58.7M -46.56M -43.82M -82.34M -5.54B -83.04M -552M -215M -2.72B -220M -216M -9.41B
Net Debt -132M -153M -121M -114M -215M -14.44B -216M -1.44B -560M -7.09B -574M -562M -24.52B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!